DiscoverBench to BedsideCancer Clinical Trials: Why Diversity Matters
Cancer Clinical Trials: Why Diversity Matters

Cancer Clinical Trials: Why Diversity Matters

Update: 2023-03-22
Share

Description

Currently, only 4 percent of people who participate in a clinical trial are Black and 5 percent are Hispanic. On this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, speaks with Dr. Tara Lin, medical director of the cancer center’s Clinical Trial Office, and Dr. Ronald Chen, Chair and professor of Radiation Oncology at the University of Kansas School of Medicine and associate director for Health Equity at the cancer center, about why diversity in clinical trials is important to the health of our region, and what The University of Kansas Cancer Center is doing to give all communities access. Ullyses Wright, a member of the cancer center’s patient research advocacy group (PIVOT) and cancer prevention clinical trial participant, also joins the conversation to share his perspective as a leader in the Kansas City African American community.

If you appreciated this episode, please share, rate, subscribe and leave a review. For the latest updates, make you are following us on social media by searching for KU Cancer Center on Facebook, Instagram and Twitter.

Do you have questions about cancer? Would you like to participate in this podcast? We want to hear from you! Send us an email with your questions at benchtobedside@kumc.edu or leave us a voice message at (913) 588-3880. Your question may be featured on a future episode.

Links from this episode:

Comments 
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Cancer Clinical Trials: Why Diversity Matters

Cancer Clinical Trials: Why Diversity Matters

The University of Kansas Cancer Center